The fate of radioisotopes infused into the lymphatics was investigated in two groups of patients. In the first group, scintiscanning was used to observe the whole body distribution of therapeutic quantities of iodine-131 Lipiodol and particular attention was given to the dose received by the lungs. In the second group of patients, lymph nodes were surgically removed following the infusion of either 1311 Lipiodol or colloidal gold-198, and the relative positions of the radioactivity and tumour in these nodes were determined.
WHOLE BODY DISTRIBUTION OF THERAPEUTIC DOSES
As a prophylactic treatment following local excision ofprimary malignant melanoma from the lower limbs, 15 patients were each given an intralymphatic infusion of Lipiodol Ultra-Fluid containing 1311-labelled triolein (LUF) using Kinmonth's technique (Kinmonth et al. 1955) . None of the patients had any clinical evidence of tumour dissemination at the time of the infusion. The total volume of inactive plus radioactive Lipiodol infused was not more than 5 ml and was administered at a rate not exceeding 0-1 ml/min. Lugol's iodine was given orally to suppress any possible thyroid uptake.
The radioactivity was observed with a whole body scintiscanner (IDL Type 6082), fitted with a detector containing a small sodium iodide crystal and a single-hole collimator. Initially the whole of each patient was scanned and subsequently the regional nodes and the chest were both repeatedly scanned for at least a week. The scans consisted of a number of marks, each one produced by a selected number of detected rays. By counting the number of marks on each scan, the rate of loss of radioiodine from the regional nodes and the chest was measured. Measurement of the activities in the nodes was not attempted because the sensitivity of the detector was depth dependent.
To estimate the activities in the lungs, experiments were performed with 'phantoms' containing known activities of 131I and composed of 'lung equivalent' material having a density of 0 33. Data were obtained on the effect of varying the air gap between the detector and the 'skin', the thickness of the 'chest wall' and the 'lung', and also the lung density, published values of which vary from 0 3 (Tow et al. 1966 ) upwards.
The Scans
No radioactivity was detected in the liver or thyroid of any patient and only small amounts were observed in the legs or near the sites of lymphatic cannulation. The regional nodes were clearly delineated (Fig 1) . Sufficient data wvere XS. ASIS, anterior suiperior iliac spine collected from 7 patients to verify that the activity in these nodes decreased exponentially with a mean effective half life of 6-9 days (range 6-3 to 7 7) corresponding to a mean biological rate of loss of 1[4% per day.
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The scans of the chests showed significant radioactivity corresponding in position and shape to the lungs. In 9 of the 15 there was an additional concentration in the region of the termination of the thoracic duct. Assuming that the rate of loss from the lungs was exponential, the mean effective half life measured from the serial scans in 6 patients was 4-5 days (range 3-6-5 3) giving a mean biological rate of loss of 6-7 % per day.
Dose to Lungs
In computing the absorbed dose of radiation it was assumed that the 1311 was uniformly distributed in a homogeneous cylinder of mass one kilogramme (International Commission of Radiological Protection 1960) and density 0 33 and also that all the beta energy was absorbed. The gamma ray absorbed fraction in the 'lung' resulted in a dose which was only 11 % of that due to the beta rays (Widman & Powsner 1967 ).
The measured half life and the activity actually infused into each patient were used to derive the mean lung doses (Table 1) When radioiodine is uniformly distributed throughout a node, the gamma dose is a negligible fraction of the beta dose and so a simple equilibrium dose formula can be applied (Loevinger & Berman 1968 ) relating the beta dose to the isotope's concentration and effective half life. The mean dose to the glands is 33,000 rads, if: (a) the recommended dose of 40 mCi is infused; (b) the lung uptake is 26 % (see Table 1 ) and the remainder of the Lipiodol is uniformly distributed in the nodes; (c) the mass of the irradiated regional nodes is 85 kg (Jantet et al. 1964 ); (d) the mean effective half life has our measured value of 6 9 days. Before accepting the validity of this dose it is necessary to verify that all the regional nodes are filled when a single peripheral lymphatic vessel is used for the infusion and that the radioactivity is uniformly distributed throughout each node. Further, if the 1311 is non-uniformly distributed, it is of interest to know if any tumour is within the range of the isotope's beta radiation.
Investigations
Regional lymph nodes were obtained by surgical block dissection from 9 patients who had previously undergone diagnostic lymphangiography with tracer doses of radioisotopes. Seven patients were given -3'I LUF and 2 received colloidal '98Au. In 2 of the patients lower limb infusions of 1311 LUF preceded removal of inguinal nodes and 7 patients had upper limb infusions prior to radical mastectomy. All the nodes were separately dissected from the excised tissue and the radioactivity in each measured with a Geiger counter apparatus.
Histological sections were prepared from the nodes containing LUF and adjacent sections taken for microscopic examination and for contact autoradiography using fine grain X-ray film. The distribution of Lipiodol within each section was thus determined, first, by visualization of the Lipiodol globules whose identification was often assisted by the presence of surrounding inflammatory cell reaction, in particular macro- 
Distributions Observed
Inter-nodal distribution: Of the 135 nodes examined 48 (36 %) contained radioactivity and the fraction filled seemed independent of the site of infusion and the radiopharmaceutical.
Ilitr-an0odal distribution of Lipiodol: The nodes were divided into two categories, those with and those without tumour, and then each category was subdivided according to the uniformity of the distribution of the Lipiodol (Table 2 ). The dose from a beta source decreases substantially in less than half of the maximum range of the rays (Table 3) , and consequently Loevinger has introduced the concept of 'Distance of Significant Dose' (Loevinger et al. 1956) defined, for Table 3 , as the distance from a point source within which 95 % of the energy of the rays is absorbed. This distance is Imm for a point source of 1311 and is less for extended sources. The distribution of 1311 was taken as uniform if all parts of the cut section were within 1 l mm of some radioactivity. The 1311 was classified as near to the tumour (separation less than l1l mm) or distant (separation greater than I * l mm).
The dose distribution was non-uniform in I I out of 16 uninvolved nodes and in all 6 of the involved nodes (Table 2 ). In 5 of the 6 involved nodes, the radioactivity was distant from the tumour, and so the latter did not receive a signi-ficant dose. In the remaining node, the tumour was so extensive that only a small part of it received a significant beta dose.
Dosimetric Appraisal ofthe Technique
Our observations indicate that, following intralymphatic infusion of 1311 LUF, the lungs receive an appreciable dose of radiation.
The infused medium, whether it is LUF or colloidal gold, seems to be sited in only a minority of the regional nodes. Further, because its distribution is insufficiently uniform, the i31I in a node is unlikely to irradiate the whole node adequately whether it contains tumour or not.
It appears to us that the probability of obtaining satisfactory prophylaxis might be increased by using a more penetrating beta emitter such as 3'P or 90Y in a medium which was confined to the lymph nodes.
